Pan Weibing, Teng Yu, Han Xiaowan, Liu Shaojiao, Pang Xingxue, Wang Lei, Zhao Mingjing
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
J Prev Alzheimers Dis. 2025 Aug;12(7):100193. doi: 10.1016/j.tjpad.2025.100193. Epub 2025 May 1.
Blood neural cell-derived small extracellular vesicles (sEVs) can directly reflect changes in brain tissue and are easier to obtain than cerebrospinal fluid. This article systematically reviews the alterations of proteins and miRNAs from neural cell-derived sEVs in patients with Alzheimer's disease (AD), and summarizes the biomarkers with clinical diagnostic and predictive value. PubMed, Web of Science, Embase, and Cochrane Library were searched for studies in blood neural cell-derived sEVs in AD patients up to May 2024. According to the inclusion and exclusion criteria, the literature was screened, the information was extracted and the quality was evaluated. Proteins and miRNAs from neural cell-derived sEVs were classified and summarized, focusing on target molecules with high diagnostic and predictive values for AD. A final 34 articles reporting 5601 participants were included. In cross-sectional studies, Aβ- and Tau-related proteins (Aβ42, Aβ42/40, p-S396-Tau, p-Tau181), p-S312-IRS-1, and cathepsin D were increased, conversely, synaptic proteins (neurogranin, synaptotagmin, synaptophysin, synaptopodin, NMDAR2A) and REST were decreased in blood neuron-derived sEVs (NDsEVs) of patients with AD. While miR-29c-3p was increased in blood NDsEVs and glial cell-derived sEVs. Each of these proteins and miRNAs demonstrated high AD diagnostic value. Additionally, blood astrocyte-derived sEVs (ADsEVs) showed increased complement effector proteins and decreased complement regulatory proteins with a moderate diagnostic value. In longitudinal cohort studies, three composite models displayed high predictive efficacy for early AD prediction, and could predict the occurrence of AD within 1-10 years. Therefore, Aβ- and Tau-related proteins, synaptic proteins, and miRNA in blood neural cell-derived sEVs demonstrate high AD diagnostic and predictive values serving as important biomarkers. Especially, synaptic proteins showed significant changes in the early clinical stage, which has early predictive value.
血液神经细胞衍生的小细胞外囊泡(sEVs)能够直接反映脑组织的变化,且比脑脊液更容易获取。本文系统综述了阿尔茨海默病(AD)患者神经细胞衍生的sEVs中蛋白质和微小RNA(miRNAs)的变化,并总结了具有临床诊断和预测价值的生物标志物。通过检索PubMed、Web of Science、Embase和Cochrane图书馆,查找截至2024年5月关于AD患者血液神经细胞衍生sEVs的研究。根据纳入和排除标准,筛选文献、提取信息并评估质量。对神经细胞衍生sEVs中的蛋白质和miRNAs进行分类总结,重点关注对AD具有高诊断和预测价值的靶分子。最终纳入34篇报道5601名参与者的文章。在横断面研究中,AD患者血液神经元衍生的小细胞外囊泡(NDsEVs)中,与淀粉样前体蛋白(Aβ)和tau蛋白相关的蛋白质(Aβ42、Aβ42/40、p-S396-Tau、p-Tau181)、p-S312-胰岛素受体底物-1(IRS-1)和组织蛋白酶D增加,相反,突触蛋白(神经颗粒蛋白、突触结合蛋白、突触囊泡蛋白、突触足蛋白、N-甲基-D-天冬氨酸受体2A(NMDAR2A))和REST减少。而血液NDsEVs和神经胶质细胞衍生的sEVs中miR-29c-3p增加。这些蛋白质和miRNAs各自都具有较高的AD诊断价值。此外,血液星形胶质细胞衍生的sEVs(ADsEVs)显示补体效应蛋白增加,补体调节蛋白减少,具有中等诊断价值。在纵向队列研究中,三种复合模型对早期AD预测显示出高预测效能,并且能够在1至10年内预测AD的发生。因此,血液神经细胞衍生sEVs中的Aβ和tau蛋白相关的蛋白质、突触蛋白和miRNA具有较高的AD诊断和预测价值,可作为重要的生物标志物。特别是,突触蛋白在临床早期阶段显示出显著变化,具有早期预测价值。